Pipeline Promise | Vir Biotechnology's HDV treatment and T-cell engager oncology programs show potential for billion-dollar peak sales, driving investor interest |
Financial Fortitude | Strong cash position funds operations into mid-2027, but negative EPS projections and cash burn rate pose challenges for long-term sustainability |
Market Volatility | Stock performance fluctuates amid clinical progress and setbacks, with analysts setting price targets ranging from $14 to $31, reflecting mixed market sentiment |
Strategic Crossroads | Vir's future hinges on HDV and TCE program success, balancing promising research with financial pressures in a competitive biotech landscape |
Metrics to compare | VIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | −1.3x | −0.2x | |
PEG Ratio | −0.12 | −0.08 | 0.00 | |
Price/Book | 1.6x | 2.4x | 2.6x | |
Price / LTM Sales | 4.7x | 5.6x | 2.6x | |
Upside (Analyst Target) | 175.6% | 172.6% | 77.0% | |
Fair Value Upside | Unlock | 17.9% | 13.7% | Unlock |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.